December 18, 2018 04:28 PM EST

Surface Oncology reins back its lead program after tracking low-dose toxicity for CD47 drug

John Carroll

Editor & Founder

Surface Oncology’s lead drug — an anti-CD47 antibody — has run into some heavy turbulence, and the Cambridge, MA-based biotech is buckling up for a rough ride …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Surface Oncology reins back its lead program after tracking low-dose toxicity for CD47 drug

John Carroll

Editor & Founder

Sign up to read this article for free.

Sr. Manager/Associate Director, Document Control

Viridian Therapeutics

Waltham, MA, USA

BridgeBio shares promising results in trial of Canavan disease gene therapy

CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study

Facing lost rebates, MGM Resorts to stop covering GLP-1 weight loss shots

Exclusive: University of Toronto spinout raises $53.5M to create new obesity drugs with AI

Icon's quarterly earnings hit by biotech and pharma pullback

IDEAYA Biosciences: Targeting unmet market needs with precision oncology

Sur­face On­col­o­gy reins back its lead pro­gram af­ter track­ing low-dose tox­i­c­i­ty for CD47 drug

Editor & Founder

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Surface Oncology reins back its lead program after tracking low-dose toxicity for CD47 drug